Aquestive Therapeutics, Inc.
Moat Score — Aquestive Therapeutics, Inc.
Total Moat Score
9 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Aquestive's PharmFilm oral thin-film drug delivery technology is protected by patents and represents genuine formulation and manufacturing know-how applicable across multiple drug products, though the underlying active ingredients in its products are typically not novel molecules. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a small specialty pharma company, Aquestive has no manufacturing scale cost advantage versus larger competitors like UCB or Neurelis in the seizure rescue therapy market. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Specialty rescue therapy pricing is generally supportable given the severity of seizure clusters, but as a later entrant Libervant must price competitively against already-established Valtoco and Nayzilam rather than setting an independent price point. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | An oral thin-film seizure rescue therapy exhibits no network effect between patients or prescribers. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once a neurologist and caregiver establish familiarity and comfort with a specific seizure rescue therapy's administration technique, there is some switching friction, but prescribers can readily choose among approved alternatives for new patients. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The seizure cluster rescue therapy market comfortably supports several competing branded products (Valtoco, Nayzilam, Libervant), so efficient-scale dynamics provide limited protection to any single later entrant like Aquestive. |